Contact the Yasmin lawsuit attorneys of Williams Hart today - 800-761-3187.

FDA approves Xarelto to treat and reduce DVT, PE

Posted on November 6th, 2012 No Comments

The U.S. Food and Drug Administration expanded Johnson & Johnson’s Xarelto drug to also include treating and reducing the risk of deep-vein thrombosis and pulmonary embolism. Xarelto is currently used to reduce the risk of blood clots and strokes.

The expansion of the drug makes Xarelto the first oral, anti-clotting drug to reduce and treat blood clots since the drug warfarin was approved almost six decades ago. Both Johnson & Johnson and Bayer market the medication, according to the Washington Post.

Deep-vein thrombosis is a blood clot that forms in one of the body’s deep, large veins–usually in the legs. These blood clots can detach and travel throughout the body, making it potentially deadly if it enters the heart or lungs. It is called a pulmonary embolism when the clot is lodged near the lungs.

If you or someone you love has suffered from deep-vein thrombosis or a pulmonary embolism caused by the birth control pills Yaz or Yasmin, contact the birth control lawsuit attorneys of Williams Hart at 800-761-3187.

Contact Williams Hart

By submitting this form, you certify that you agree to our terms and conditions and wish to be contacted regarding your inquiry.

Williams Hart Represents Yasmin/Yaz Victims Nationwide

Williams Hart represents clients across the country. Click here to learn more.

home  |  about us  |  attorneys  |  yaz  |  yasmin  |  ocella  |  faqs  |  articles  |  contact us  |  blog  |  Legal Colleagues  |  Log in
Copyright ©2007-2009 Williams Hart. Attorneys are licensed only in the state of Texas unless otherwise indicated in the biographical section. Past performance is no guarantee of future results. Williams Hart's main office is located in Houston, Texas. Terms of Use. Disclaimer.
8441 Gulf Freeway, Suite 600, Houston, TX 77017-5051 -- 800-761-3187

Search Engine Optimization provided by The Search Engine Guys.